1. bookTom 30 (2022): Zeszyt 2 (April 2022)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2284-5623
Pierwsze wydanie
08 Aug 2013
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
access type Otwarty dostęp

MMP-2 and MMP-9 gene polymorphisms and risk of head and neck carcinomas

Data publikacji: 09 May 2022
Tom & Zeszyt: Tom 30 (2022) - Zeszyt 2 (April 2022)
Zakres stron: 163 - 171
Otrzymano: 10 Jun 2021
Przyjęty: 28 Jan 2022
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2284-5623
Pierwsze wydanie
08 Aug 2013
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
Abstract

Background: Head and neck carcinomas (HNC) account for a majority of ear, nose and throat tumours. They account for 6.3% of all incident malignancies and 6.2 % of all deaths from cancer in Romania in 2020, the fifth most common cancer in this Eastern Europe country. Aim of the study: The aim of our study was to investigate the association between two MMP-2 and MMP-9 promoter gene polymorphisms and head and neck cancer.

Methods. We enrolled 142 subjects, 65 cancer patients, and 77 control subjects and tested them for MMP-2 -735 C/T and MMP-9 -1562 C/T polymorphisms by PCR-RFLP.

Results. Comparison between cancer patients and controls demonstrated the presence of MMP-2 -735 C/T and MMP-9 -1562 C/T in head and neck malignant tumours, with OR = 2.206 (95% CI 1.058-4.599, P = 0.03) for MMP-2 and OR = 2.748 (95% C.I. 1.262-5.981, P=0.009) for MMP-9 gene polymorphism. This means that the presence of T allele could be a risk factor for head and neck cancer development. The analysis included a stratification of studied groups by age and gender.

Conclusions. Both genotypes were associated with a significant risk for head and neck carcinomas in case of the presence of the T allele. MMP-2 -735 C/T (rs2285053) and MMP-9 -1562 C/T (rs3918242) gene polymorphism could be an important genetic marker for head and neck cancer susceptibility. This finding could be useful for genetic screening in head and neck carcinomas.

Keywords

1. Monteiro LS, Antunes L, Santos LL, Bento MJ, Warnakulasuriya S. Survival probabilities and trends for lip, oral cavity and oropharynx cancers in Northern Portugal in the period 2000-2009. Ecancermedical-science. 2018;12:855. DOI: 10.3332/ecancer.2018.85510.3332/ecancer.2018.855 Search in Google Scholar

2. Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013 May;25(3):229-34. DOI: 10.1097/CCO.0b013e32835ff48c10.1097/CCO.0b013e32835ff48c Search in Google Scholar

3. Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base Report on Cancer of the Head and Neck. Arch Otolaryngol Head Neck Surg. 1998 Sep 1;124(9):951. DOI: 10.1001/archotol.124.9.95110.1001/archotol.124.9.951 Search in Google Scholar

4. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. The Lancet. 2008 May;371(9625):1695-709. DOI: 10.1016/S0140-6736(08)60728-X10.1016/S0140-6736(08)60728-X Search in Google Scholar

5. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pi-eros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-53. DOI: 10.1002/ijc.3193710.1002/ijc.3193730350310 Search in Google Scholar

6. Jimenez L, Jayakar SK, Ow TJ, Segall JE. Mechanisms of Invasion in Head and Neck Cancer. Archives of Pathology & Laboratory Medicine. 2015 Nov 1;139(11):1334-48. DOI: 10.5858/arpa.2014-0498-RA10.5858/arpa.2014-0498-RA746995126046491 Search in Google Scholar

7. Dhull AK, Atri R, Dhankhar R, Chauhan AK, Kaushal V. Major Risk Factors in Head and Neck Cancer: A Retrospective Analysis of 12-Year Experiences. World J Oncol. 2018;9(3):80-4. DOI: 10.14740/wjon1104w10.14740/wjon1104w603123129988794 Search in Google Scholar

8. Sturgis EM, Wei Q. Genetic susceptibility-molecular epidemiology of head and neck cancer: Current Opinion in Oncology. 2002 May;14(3):310-7. DOI: 10.1097/00001622-200205000-0001010.1097/00001622-200205000-0001011981277 Search in Google Scholar

9. Lacko M, Oude Ophuis MB, Peters WHM, Manni JJ. Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res. 2009 Feb;29(2):753-61. Search in Google Scholar

10. Freije JMP, Balbín M, Pendás AM, Sánchez LM, Puente XS, López-Otín C. Matrix Metalloproteinases and Tumor Progression. In: Llombart-Bosch A, Felipo V, editors. New Trends in Cancer for the 21stCentury [Internet]. Boston, MA: Springer US; 2003 [cited 2021 Jun 16]. p. 91-107. (Advances in Experimental Medicine and Biology; vol. 532). DOI: 10.1007/978-1-4615-0081-0_910.1007/978-1-4615-0081-0_912908552 Search in Google Scholar

11. Bellayr IH, Mu X, Li Y. Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments. Future Med Chem. 2009 Sep;1(6):1095-111. DOI: 10.4155/fmc.09.8310.4155/fmc.09.83279413820161478 Search in Google Scholar

12. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007 Jun;29(6):564-72. DOI: 10.1002/hed.2056110.1002/hed.20561 Search in Google Scholar

13. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Delivery. 2015 Aug 18;22(6):849-61. DOI: 10.3109/10717544.2014.89834810.3109/10717544.2014.898348 Search in Google Scholar

14. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncology. 2000 Mar;36(2):207-13. DOI: 10.1016/S1368-8375(99)00088-310.1016/S1368-8375(99)00088-3 Search in Google Scholar

15. Vilen S-T, Salo T, Sorsa T, Nyberg P. Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma. The Sci World J. 2013;2013:1-11. DOI: 10.1155/2013/92059510.1155/2013/920595 Search in Google Scholar

16. Kessenbrock K, Plaks V, Werb Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell. 2010 Apr;141(1):52-67. DOI: 10.1016/j. cell.2010.03.015 Search in Google Scholar

17. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck: Correlation with p53 status, inducible nitric oxide synthase activity, and angiogenesis. Cancer. 2002 Nov 1;95(9):1902-10. DOI: 10.1002/cncr.1091610.1002/cncr.10916 Search in Google Scholar

18. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem. 1990 Jul 5;265(19):11077-82. DOI: 10.1016/S0021-9258(19)38559-X10.1016/S0021-9258(19)38559-X Search in Google Scholar

19. Qin H, Sun Y, Benveniste EN. The Transcription Factors Sp1, Sp3, and AP-2 Are Required for Constitutive Matrix Metalloproteinase-2 Gene Expression in Astroglioma Cells. Journal of Biological Chemistry. 1999 Oct;274(41):29130-7. DOI: 10.1074/jbc.274.41.2913010.1074/jbc.274.41.2913010506168 Search in Google Scholar

20. Price SJ, Greaves DR, Watkins H. Identification of Novel, Functional Genetic Variants in the Human Matrix Metalloproteinase-2 Gene. Journal of Biological Chemistry. 2001 Mar;276(10):7549-58. DOI: 10.1074/jbc.M01024220010.1074/jbc.M01024220011114309 Search in Google Scholar

21. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional Haplotypes in the Promoter of Matrix Metalloproteinase-2 Predict Risk of the Occurrence and Metastasis of Esophageal Cancer. Cancer Res. 2004 Oct 15;64(20):7622-8. DOI: 10.1158/0008-5472.CAN-04-152110.1158/0008-5472.CAN-04-152115492291 Search in Google Scholar

22. Zhang B, Ye S, Herrmann S-M, Eriksson P, de Maat M, Evans A, et al. Functional Polymorphism in the Regulatory Region of Gelatinase B Gene in Relation to Severity of Coronary Atherosclerosis. Circulation. 1999 Apr 13;99(14):1788-94. DOI: 10.1161/01.CIR.99.14.178810.1161/01.CIR.99.14.178810199873 Search in Google Scholar

23. Iizuka S, Ishimaru N, Kudo Y. Matrix Metalloproteinases: The Gene Expression Signatures of Head and Neck Cancer Progression. Cancers. 2014 Feb 13;6(1):396-415. DOI: 10.3390/cancers601039610.3390/cancers6010396398059224531055 Search in Google Scholar

24. O-Charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20. Search in Google Scholar

25. Zhang H, Li G, Zhang Z, Wang S, Zhang S. MMP-2 and MMP-9 gene polymorphisms associated with cervical cancer risk. Int J Clin Exp Pathol. 2017 Dec 1;10(12):11760-5. Search in Google Scholar

26. Habel AF, Ghali RM, Bouaziz H, Daldoul A, Hadj-Ahmed M, Mokrani A, et al. Common matrix metalloproteinase-2 gene variants and altered susceptibility to breast cancer and associated features in Tunisian women. Tumour Biol. 2019 Apr;41(4):101042831984574. DOI: 10.1177/101042831984574910.1177/101042831984574931014197 Search in Google Scholar

27. Yari K, Rahimi Z, Moradi MT, Rahimi Z. The MMP-2 -735 C Allele is a Risk Factor for Susceptibility to Breast Cancer. Asian Pacific Journal of Cancer Prevention. 2014 Aug 15;15(15):6199-203. DOI: 10.7314/APJCP.2014.15.15.619910.7314/APJCP.2014.15.15.619925124598 Search in Google Scholar

28. Beeghly-Fadiel A, Lu W, Long J-R, Shu X, Zheng Y, Cai Q, et al. Matrix Metalloproteinase-2 Polymorphisms and Breast Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1770-6. DOI: 10.1158/1055-9965.EPI-09-012510.1158/1055-9965.EPI-09-0125274704419454611 Search in Google Scholar

29. Rollin J, Régina S, Vourc’h P, Iochmann S, Bléchet C, Reverdiau P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007 May;56(2):273-80. DOI: 10.1016/j.lung-can.2006.11.021 Search in Google Scholar

30. Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010 Jul 1;25(4):371-9. DOI: 10.1093/mutage/geq01510.1093/mutage/geq01520360147 Search in Google Scholar

31. Shao JY, Cao Y, Miao XP, Huang MY, Deng L, Hao JJ, et al. A single nucleotide polymorphism in the matrix metalloproteinase 2 promoter is closely associated with high risk of nasopharyngeal carcinoma in Cantonese from southern China. Chin J Cancer. 2011 Sep 5;30(9):620-6. DOI: 10.5732/cjc.010.1059210.5732/cjc.010.10592401332421880183 Search in Google Scholar

32. Sharma KL, Misra S, Kumar A, Mittal B. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int. 2012 Sep;32(8):1278-86. DOI: 10.1111/j.1478-3231.2012.02822.x10.1111/j.1478-3231.2012.02822.x22621753 Search in Google Scholar

33. Zhai Y, Qiu W, Dong XJ, Zhang XM, Xie WM, Zhang HX, et al. Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut. 2007 Mar 1;56(3):445-7. DOI: 10.1136/gut.2006.11270610.1136/gut.2006.112706185678717339256 Search in Google Scholar

34. Tsai CW, Hsu HM, Wang YC, Chang WS, Shih LC, Sun KT, et al. Contribution of MMP2 Promoter Genotypes to Oral Cancer Susceptibility, Recurrence and Metastasis in Taiwan. Anticancer Res. 2018 Dec;38(12):6821-6. DOI: 10.21873/anticanres.1305510.21873/anticanres.1305530504396 Search in Google Scholar

35. O-charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metal-loproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncology. 2006 Mar;42(3):257-67. DOI: 10.1016/j.oraloncology.2005.07.00810.1016/j.oraloncology.2005.07.00816275157 Search in Google Scholar

36. Rosenthal EL, Matrisian LM. Matrix metallopro-teases in head and neck cancer. Head Neck. 2006 Jul;28(7):639-48. DOI: 10.1002/hed.2036510.1002/hed.20365287321716470875 Search in Google Scholar

37. Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. Role of functional polymorphism of matrix metal-loproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers. 2011 Nov;16(7):577-86. DOI: 10.3109/1354750X.2011.60960210.3109/1354750X.2011.60960221958210 Search in Google Scholar

38. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Human Genetics. 1999 Nov 15;105(5):418-23. DOI: 10.1007/s00439005112410.1007/s00439005112410598806 Search in Google Scholar

39. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, et al. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol(EJSO). 2008 Apr;34(4):450-5. DOI: 10.1016/j.ejso.2007.03.02410.1016/j.ejso.2007.03.02417498910 Search in Google Scholar

40. Nascimento, GJ Ferreira do et al. Polymorphisms of matrix metalloproteinase-7 and -9 are associated with oral tongue squamous cell carcinoma. Brazilian Oral Res [online]. 2021, v. 35, e019. DOI: 10.1590/1807-3107bor-2021.vol35.001910.1590/1807-3107bor-2021.vol35.001933237244 Search in Google Scholar

41. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, et al. Meta-Analysis of MMP2, MMP3, and MMP9 Promoter Polymorphisms and Head and Neck Cancer Risk. Creighton C, editor. PLoS ONE. 2013 Apr 24;8(4):e62023. DOI: 10.1371/journal.pone.006202310.1371/journal.pone.0062023363472923637955 Search in Google Scholar

42. Xu T, Zhang S, Qiu D, Li X, Fan Y. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: An updated meta-analysis and trial sequential analysis. Gene. 2020 Oct;759:144972. DOI: 10.1016/j.gene.2020.14497210.1016/j.gene.2020.14497232739585 Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo